Compare IDXX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | BDX |
|---|---|---|
| Founded | 1983 | 1897 |
| Country | United States | United States |
| Employees | 11000 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 51.5B |
| IPO Year | 1996 | 1996 |
| Metric | IDXX | BDX |
|---|---|---|
| Price | $557.97 | $147.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $721.67 | $186.00 |
| AVG Volume (30 Days) | 578.8K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 3.47 | 0.25 |
| Revenue | $4,303,702,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $10.88 | N/A |
| Revenue Next Year | $8.59 | $3.02 |
| P/E Ratio | ★ $159.66 | $585.62 |
| Revenue Growth | ★ 10.42 | 8.24 |
| 52 Week Low | $504.56 | $141.82 |
| 52 Week High | $769.98 | $213.08 |
| Indicator | IDXX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 46.76 |
| Support Level | $554.61 | N/A |
| Resistance Level | $595.15 | $158.66 |
| Average True Range (ATR) | 19.51 | 4.48 |
| MACD | 1.96 | 0.60 |
| Stochastic Oscillator | 55.62 | 39.86 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.